Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

How to use ETFs in your portfolio

Bell Direct
July 28, 2020

Morning Bell 28 July

Jessica Amir
July 28, 2020

Morning Bell 27 July

Jessica Amir
July 27, 2020

Weekly Wrap 24 July

Jessica Amir
July 24, 2020

Morning Bell 24 July

Paulina Peters
July 24, 2020

Morning Bell 23 July

Jessica Amir
July 23, 2020

Morning Bell 22 July

Jessica Amir
July 22, 2020

Morning Bell 21 July

Jessica Amir
July 21, 2020

Morning Bell 20 July

Jessica Amir
July 20, 2020

Weekly Wrap 17 July

Bell Direct
July 17, 2020

Morning Bell 17 July

Jessica Amir
July 17, 2020